Alnylam Pharma Appoints New Chief R&D Officer

Alnylam Pharma ( (ALNY) ) has shared an announcement.

On June 12, 2025, Alnylam Pharmaceuticals announced the integration of its Research and Early Development function with its Development function into a single organization, appointing Pushkal Garg as Executive Vice President, Chief Research and Development Officer. This strategic move aims to accelerate pipeline progress and foster collaboration, enhancing Alnylam’s ability to deliver RNAi therapeutics to all major tissues by 2030, thus potentially transforming patient care across a range of diseases.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Spark’s Take on ALNY Stock

According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.

Alnylam Pharmaceuticals is showing promising revenue growth and strong technical momentum, contributing positively to its stock score. However, high leverage, ongoing profitability challenges, and a negative P/E ratio weigh down the overall evaluation. The company’s strategic focus on achieving sustainable profitability and recent successful product launches provide optimism, but caution is advised due to financial and regulatory risks.

To see Spark’s full report on ALNY stock, click here.

More about Alnylam Pharma

Alnylam Pharmaceuticals, Inc. is a leading company in the RNA interference (RNAi) therapeutics industry, focusing on developing innovative medicines for rare and prevalent diseases with unmet needs. Based on Nobel Prize-winning science, Alnylam has a deep pipeline of investigational medicines and is executing on its ‘Alnylam P5x25’ strategy to deliver transformative medicines globally.

Average Trading Volume: 1,039,317

Technical Sentiment Signal: Buy

Current Market Cap: $40.26B

For a thorough assessment of ALNY stock, go to TipRanks’ Stock Analysis page.